Argenx NV ADR stock hits all-time high of 855.68 USD

Argenx NV ADR stock reached an all-time high of 855.68 USD, marking a significant milestone for the biotechnology firm with a market capitalization of $52.22 billion. Over the past year, the stock has demonstrated impressive growth, with a 1-year return of 41.32% and a substantial six-month gain of 35.32%. This surge reflects strong investor confidence and the company's robust performance in the biopharmaceutical sector, evidenced by its remarkable 92.98% revenue growth over the last twelve months. The achievement of this all-time high underscores the market's positive reception to Argenx's strategic initiatives and advancements in its product pipeline. InvestingPro analysis indicates the stock is slightly undervalued, with analysts maintaining a strong buy consensus. For deeper insights including 16 ProTips and comprehensive analysis, check out the Pro Research Report available on InvestingPro.

In other recent news, argenx SE reported strong third-quarter results with Vyvgart generating $1.13 billion in revenue, marking a 19% increase from the previous quarter and a 96% increase year-over-year. This revenue exceeded consensus estimates of $1.06 billion, highlighting the robust uptake of Vyvgart across multiple indications and formulations. Analysts responded positively to these results, with Piper Sandler raising its price target for argenx to $930 and maintaining an Overweight rating due to the company's strong performance. Similarly, TD Cowen increased its price target to $1,146, citing a solid third-quarter beat and the global strength of the Vyvgart brand.

Stifel also raised its price target to $882, reflecting confidence in argenx's maturing pipeline, particularly after positive data in seronegative myasthenia gravis. Oppenheimer reaffirmed its Outperform rating following positive clinical proof of concept data in congenital myasthenic syndromes. These developments underscore the continued strong adoption of Vyvgart and the potential of argenx's pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.